Jones Day leads Daily Journal’s list of "Top Intellectual Property Lawyers" in California for 2021

Jones Day partners Michael Hendershot, Anthony M. Insogna, Andrea Jeffries, and Randy Kay are among the "Top Intellectual Property Lawyers" in California selected by the Daily Journal for 2021. This is the second consecutive year that the Daily Journal has honored this group of Firm partners. No other firm had as many lawyers recognized and Jones Day was the only firm with attorneys recognized in each of California’s major IP markets in Northern California, Los Angeles, and San Diego.

Mike Hendershot (Silicon Valley), who leads the Firm's Northern California IP practice, is a trial lawyer who has focused on patent and trade secret litigation for two decades. He has delivered successful litigation results across the country, including jury wins in the Eastern District of Texas and Delaware. Throughout his career, Mike has advised a range of industry leaders on their most challenging IP matters, such as representing eBay from trial through its landmark Supreme Court victory in eBay v. MercExchange. Judges, clients, and opposing counsel have commended his ability to clearly marshal complex technologies for judges and jurors in a way that is approachable and that reinforces winning case themes, with in-house counsel having described Mike's likability with jurors as "off the charts." He has recently represented Google in a number of patent cases involving a variety of technologies in which he helped obtain transfers, dismissals, and summary judgment, and, in one case, invalidated 177 patent claims. Mike also recently won a patent case for Twilio, successfully arguing invalidity in the District of Delaware's first telephonic "Section 101 Day," and defended Cohesity's innovative data management and storage technology in a range of IP and litigation matters.

Anthony M. Insogna (San Diego) leads the Firm's global Intellectual Property Practice, with more than 220 professionals in 27 cities across eight countries. Mr. Insogna has over 30 years of experience handling high-stakes patent litigation, technology-driven transactions, and global IP strategies for life sciences companies. He is a trusted advisor to many of the world's top-tier pharmaceutical and biotech innovators, with extensive experience enforcing and defending patents involving the world's top-selling pharmaceuticals. Among Mr. Insogna's current matters are his representation of Celgene, a Bristol Myers Squibb company, in its most important Abbreviated New Drug Application litigation involving REVLIMID® and POMALYST®. He also represents Merck & Co. in Hatch-Waxman patent infringement actions against 16 entities seeking approval of generic versions of BRIDION®. Mr. Insogna also regularly advises and represents companies seeking protection for their cutting-edge technologies, such as revolutionary immuno-oncology drugs, CRISPR-Cas9 (gene editing), gene therapies, and vaccines. He currently leads a team representing ToolGen, a Korean biotech company, in two patent interferences involving CRISPR/Cas9 technology, which follow on the heels of Mr. Insogna's successful argument before the PTAB to reverse the examiner's claim rejections.

Andrea Jeffries (Los Angeles), who leads the Firm's Los Angeles IP practice, is an experienced first-chair IP litigator who leads significant matters involving patents, trade secrets, and other forms of IP across a range of technologies, including pharmaceuticals, medical devices, semiconductors, and wireless communications. Most recently, in the life sciences sector, Ms. Jeffries has represented major pharmaceutical companies in high-stakes patent litigation matters. On behalf of patentee Sloan Kettering Institute and exclusive licensee Juno Therapeutics (a subsidiary of Celgene, a Bristol Myers Squibb company), Ms. Jeffries led the Jones Day team that recently prevailed, with co-counsel, in a jury trial, winning $752 million for infringement by Kite Pharma (a Gilead Sciences company). The district court denied Kite's post-trial motions and granted-in-part those filed by Juno, resulting in a win of over $1.1 billion. Ms. Jeffries is currently leading a Jones Day team and co-counsel representing Merck Sharp & Dohme in an action in Delaware district court against Wyeth, seeking declaratory judgment of invalidity and noninfringement of patents relating to a new 15-valent pneumococcal conjugate vaccine. She is also representing Merck & Co. in the Hatch-Waxman actions involving BRIDION®.

Randy Kay (San Diego) is an IP trial lawyer with more than 30 years of experience litigating in courtrooms across the country. He predominantly represents IP owners in trade secret, misuse of confidential information, and patent disputes. Mr. Kay has led more than 30 trials and arbitrations in federal and state courts, arbitral forums, and the International Trade Commission involving a wide range of technologies. He also handles IP appeals in federal and state courts. Mr. Kay has particularly deep experience with trade secret disputes involving failed collaborations, employee departures, and data breaches. His trade secret practice often involves complex disputes with international players and events occurring cross-border. Mr. Kay currently leads several global trade secret disputes including two of the first Defend Trade Secrets Act cases filed by U.S.-based companies against foreign actors whose misappropriation took place primarily on foreign soil. Widely considered a trade secret thought leader, Mr. Kay has spoken at engagements worldwide regarding the strength of U.S. trade secret protection as a model for other countries to follow.

Jones Day is a global law firm with more than 2,500 lawyers in 42 offices across five continents. The Firm is distinguished by: a singular tradition of client service; the mutual commitment to, and the seamless collaboration of, a true partnership; formidable legal talent across multiple disciplines and jurisdictions; and shared professional values that focus on client needs.